Exploring the Use of Biologics in the Management of Lupus Nephritis: A Clinical Case Conference

What you'll learn

Course overview

Lupus nephritis is a severe complication that develops in up to 60% of individuals with systemic lupus erythematosus (SLE). Characterized by kidney inflammation and chronic parenchymal damage, lupus nephritis leads to progressive kidney damage and potential kidney failure, representing one of the leading causes of morbidity and mortality among patients with SLE. The emergence of novel biological agents and combination therapies has provided a promising new approach to the treatment of lupus nephritis. This Clinical Case Conference will explore 3 complex case studies illustrating the use of novel therapies and combinations in the management of lupus nephritis (Wiegley et al, 2024). It features perspectives from Anca Askanase, MD, Professor of Medicine, Director of the Lupus Center, and Director of Rheumatology Clinical Trials at Columbia University Irving Medical Center; Andrew Bomback, MD, MPH, Associate Professor of Medicine and Co-Director of the Center for Glomerular Diseases at Columbia University Irving Medical Center; and Samir Parikh, MD, Clinical Professor of Internal Medicine in the Division of Nephrology at The Ohio State University Wexner Medical Center.